STAT+: Pharmalittle: EMA finds link between AstraZeneca shot and rare blood clots; life science private financing is at record levels

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of glazed doughnut for the occasion. Meanwhile, our ever-growing to-do list needs attention. Sound familiar? So … here are some items of interest. Have a great day, everyone. …

The European Medicines Agency concluded there is a link between the AstraZeneca (AZN) Covid-19 vaccine and “very rare” but dangerous clotting events reported in a number of countries where the vaccine has been used, events which in some cases have been fatal, STAT says. A safety committee concluded “unusual blood clots with low blood platelets should be listed as very rare side effects.” Regulators stressed the benefits of the vaccine, which was 76% effective at preventing Covid infections in a large U.S.-based study, still outweigh its risks.

Continue to STAT+ to read the full story…